Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritisRheumatic & musculoskeletal diseases open, 2018, Vol.4 (1), p.e000649-e000649 [Peer Reviewed Journal]Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;2018 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2018 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2018-000649 ;PMID: 29862045Full text available |
|
2 |
Material Type: Article
|
Validating 10-joint juvenile arthritis disease activity score cut-offs for disease activity levels in non-systemic juvenile idiopathic arthritisRheumatic & musculoskeletal diseases open, 2019-04, Vol.5 (1), p.e000888 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. 2019 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2018-000888 ;PMID: 31168410Full text available |
|
3 |
Material Type: Article
|
Association between osteoarthritis and dyslipidaemia: a systematic literature review and meta-analysisRheumatic & musculoskeletal diseases open, 2017-08, Vol.3 (2), p.e000442-e000442 [Peer Reviewed Journal]Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;Copyright: 2017 © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;Distributed under a Creative Commons Attribution 4.0 International License ;Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2017 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2017-000442 ;PMID: 29435358Full text available |
|
4 |
Material Type: Article
|
Antirheumatic drugs and reproduction in women and men with chronic arthritisRheumatic & musculoskeletal diseases open, 2015-08, Vol.1 (Suppl 1), p.e000048 [Peer Reviewed Journal]Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2015 This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2015 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2015-000048 ;PMID: 26557371Full text available |
|
5 |
Material Type: Article
|
Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registryRheumatic & musculoskeletal diseases open, 2019-07, Vol.5 (2), p.e000969-e000969 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2019 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2019-000969 ;PMID: 31413867Full text available |
|
6 |
Material Type: Article
|
Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinibRheumatic & musculoskeletal diseases open, 2019-02, Vol.5 (1), p.e000742-e000742 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2019 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2018-000742 ;PMID: 30886732Full text available |
|
7 |
Material Type: Article
|
Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practiceRheumatic & musculoskeletal diseases open, 2019-11, Vol.5 (2), p.e001050-e001050 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. 2019 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2019-001050 ;PMID: 31908842Full text available |
|
8 |
Material Type: Article
|
Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over timeRheumatic & musculoskeletal diseases open, 2019-01, Vol.5 (1), p.e000836-e000836 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2019 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2018-000836 ;PMID: 30740244Full text available |
|
9 |
Material Type: Article
|
Rituximab in early systemic sclerosisRheumatic & musculoskeletal diseases open, 2017-07, Vol.3 (2), p.e000384-e000384 [Peer Reviewed Journal]Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;Copyright: 2017 © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2017 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2016-000384 ;PMID: 28879049Full text available |
|
10 |
Material Type: Article
|
Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitisRheumatic & musculoskeletal diseases open, 2023-08, Vol.9 (3), p.e003102 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2023-003102 ;PMID: 37652557Full text available |
|
11 |
Material Type: Article
|
Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritisRheumatic & musculoskeletal diseases open, 2019-08, Vol.5 (2), p.e000922-e000922 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2019 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2019-000922 ;PMID: 31565240Full text available |
|
12 |
Material Type: Article
|
Systemic lupus erythematosus and fracturesRheumatic & musculoskeletal diseases open, 2015-08, Vol.1 (Suppl 1), p.e000069-e000069 [Peer Reviewed Journal]Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2015 This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2015 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2015-000069 ;PMID: 26557383Full text available |
|
13 |
Material Type: Article
|
Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritisRheumatic & musculoskeletal diseases open, 2020-01, Vol.6 (1), p.e001032 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2020 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2019-001032 ;PMID: 31958278Full text available |
|
14 |
Material Type: Article
|
Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entityRheumatic & musculoskeletal diseases open, 2017-01, Vol.3 (1), p.e000412-e000412 [Peer Reviewed Journal]Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Copyright: 2017 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2017 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2016-000412 ;PMID: 28405474Full text available |
|
15 |
Material Type: Article
|
Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphismRheumatic & musculoskeletal diseases open, 2023-03, Vol.9 (1), p.e002935 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2022-002935 ;PMID: 36990659Full text available |
|
16 |
Material Type: Article
|
Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritisRheumatic & musculoskeletal diseases open, 2021-03, Vol.7 (1), p.e001228 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2020-001228 ;PMID: 33771834Full text available |
|
17 |
Material Type: Article
|
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trialsRheumatic & musculoskeletal diseases open, 2019-01, Vol.5 (1), p.e000763-e000763 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Attribution - NonCommercial ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2019 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2018-000763 ;PMID: 30792887Full text available |
|
18 |
Material Type: Article
|
Don’t neglect nutrition in rheumatoid arthritisRheumatic & musculoskeletal diseases open, 2018-01, Vol.4 (1), p.e000591-e000591 [Peer Reviewed Journal]Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;2018 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2018 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2017-000591 ;PMID: 29531785Full text available |
|
19 |
Material Type: Article
|
Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologicRheumatic & musculoskeletal diseases open, 2017-01, Vol.3 (1), p.e000473-e000473 [Peer Reviewed Journal]Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;Copyright: 2017 © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2017 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2017-000473 ;PMID: 28955489Full text available |
|
20 |
Material Type: Article
|
MDHAQ/RAPID3 scores in patients with osteoarthritis are similar to or higher than in patients with rheumatoid arthritis: a cross-sectional study from current routine rheumatology care at four sitesRheumatic & musculoskeletal diseases open, 2017-01, Vol.3 (1), p.e000391-e000391 [Peer Reviewed Journal]Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;Copyright: 2017 © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2017 ;ISSN: 2056-5933 ;EISSN: 2056-5933 ;DOI: 10.1136/rmdopen-2016-000391 ;PMID: 29225915Full text available |